Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Local immunotherapy in allergy.

David L Morris1, George F Kroker, Vijay K Sabnis

  • 1Allergy Associates of La Crosse, Ltd., La Crosse, Wisc 54602-2408, USA. dmorris@allergysolutions.com

Chemical Immunology and Allergy
|September 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct Patterns of Colorectal Peritoneal Metastases at Initial and Repeat Cytoreductive Surgery.

World journal of surgery·2026
Same author

Mucin O-Glycosylation and Mucolytic Therapies in Pseudomyxoma Peritonei: Literature Review.

Medicinal research reviews·2026
Same author

The association between preoperative ROTEM-assessed hypercoagulability and postoperative pulmonary embolism in cytoreductive surgery and HIPEC: a single-site Bayesian analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Preclinical assessment of inhalational subacute safety of nebulized MP-171 (BromAc®).

BMC pulmonary medicine·2026
Same author

The addition of collagenase to BromAc <sup><b>®</b></sup> for the management of inoperable pseudomyxoma peritonei - <i>in vitro</i> results.

Pleura and peritoneum·2025
Same author

Overall survival post secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal cancer with peritoneal metastases.

World journal of surgical oncology·2025
Same journal

Educational programmes in food allergy.

Chemical immunology and allergy·2015
Same journal

Prevention of food allergy.

Chemical immunology and allergy·2015
Same journal

The effects of food allergy on quality of life.

Chemical immunology and allergy·2015
Same journal

Worldwide food allergy labeling and detection of allergens in processed foods.

Chemical immunology and allergy·2015
Same journal

Food allergy: psychosocial impact and public policy implications.

Chemical immunology and allergy·2015
Same journal

Nutritional aspects and diets in food allergy.

Chemical immunology and allergy·2015
See all related articles

Sublingual immunotherapy (SLIT) offers a safe and convenient alternative to traditional allergy shots. This treatment effectively improves allergy symptoms and reduces medication needs, making it a recommended first-line option.

Area of Science:

  • Allergy and Immunology
  • Immunotherapy

Background:

  • Specific immunotherapy is an underutilized but powerful allergy treatment.
  • Sublingual immunotherapy (SLIT) presents advantages over subcutaneous immunotherapy (SCIT).
  • SLIT is well-established for pollens and dust mites, particularly in Europe.

Purpose of the Study:

  • To highlight the benefits and efficacy of sublingual immunotherapy.
  • To advocate for SLIT as a first-line treatment option for allergies.

Main Methods:

  • Review of multiple studies on sublingual immunotherapy efficacy and safety.
  • Consideration of World Health Organization endorsement.

Main Results:

  • SLIT has been proven effective for various allergens like pollens and dust mites.

Related Experiment Videos

  • Studies demonstrate SLIT improves allergy symptoms and decreases medication dependence.
  • SLIT offers a viable alternative to SCIT for many patients.

    • Conclusions:

    • Sublingual immunotherapy provides a valuable treatment option for patients unsuitable for SCIT.
    • Improved safety, convenience, and compliance support SLIT's use as a first-line therapy.